Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
ChiCTR-OPC-17010671Phase 4Not yet recruiting
- Sponsor
- Qinghai Red Cross Hospital
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Cervical Cancer (CC), sponsored by Qinghai Red Cross Hospital. Primary endpoints: Disease-free survival (DFS) and Objective response rate (ORR). Planned start Mar 2017; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR-OPC-17010671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010671.